These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18687456)

  • 41. The challenges of technological innovation in HIV.
    Rosengarten M; Michael M; Mykhalovskiy E; Imrie J
    Lancet; 2008 Aug; 372(9636):357-8. PubMed ID: 18675674
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies.
    Eaton LA; Kalichman S
    Curr HIV/AIDS Rep; 2007 Dec; 4(4):165-72. PubMed ID: 18366947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?
    Gray GE; Laher F; Doherty T; Abdool Karim S; Hammer S; Mascola J; Beyrer C; Corey L
    PLoS Biol; 2016 Mar; 14(3):e1002372. PubMed ID: 26933962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control groups for HIV prevention efficacy trials: what does the future hold?
    Janes H; Buchbinder S
    Curr Opin HIV AIDS; 2023 Nov; 18(6):349-356. PubMed ID: 37712852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public health's social contract: An obstacle in the advancement of effective HIV technologies.
    Bulled N
    Glob Public Health; 2019 Sep; 14(9):1264-1274. PubMed ID: 30810469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention.
    Roberts ET; Matthews DD
    Soc Sci Med; 2012 Nov; 75(9):1555-61. PubMed ID: 22495513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The myth of a naturalised male circumcision: Heuristic context and the production of scientific objects.
    Brives C
    Glob Public Health; 2018 Nov; 13(11):1599-1611. PubMed ID: 29237325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re-shaping HIV Interventions with Technology.
    Ragsdale A; Rotheram-Borus MJ
    AIDS Behav; 2015 Jun; 19 Suppl 2(0 2):77-80. PubMed ID: 26088905
    [No Abstract]   [Full Text] [Related]  

  • 49. Which of these things is not like the others?
    Kaufman JS; MacLehose RF
    Cancer; 2013 Dec; 119(24):4216-22. PubMed ID: 24022386
    [No Abstract]   [Full Text] [Related]  

  • 50. Innovative Use of Technology for HIV Prevention and Care: Evidence, Challenges and the Way Forward.
    Young S; Chiu J
    J Mob Technol Med; 2014; 3(15):1-3. PubMed ID: 25530815
    [No Abstract]   [Full Text] [Related]  

  • 51. Attitudes Toward the Uptake of Combination HIV Prevention Methods Among Young Black and Latino Heterosexual Couples Living in New York City: A Qualitative Study.
    Lanier Y; Lui N; Zhong J; Rivera-Cash D; Cornelius T; Stewart JM
    J Assoc Nurses AIDS Care; 2024 May-Jun 01; 35(3):281-293. PubMed ID: 38546533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing behavioral economic biases among young adults who have increased likelihood of acquiring HIV: a mixed methods study in Baltimore, Maryland.
    Jennings Mayo-Wilson L; Coleman Lewis J; MacCarthy S; Linnemayr S
    AIDS Res Ther; 2023 May; 20(1):25. PubMed ID: 37150823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applying mathematical modelling to estimate the impact of COVID-19-related VMMC service disruptions on new HIV infections in Zimbabwe.
    Chagoma N; Kanyenda T; Pindiwe B; Nyika H; Nyazema L; Stover J; Resar D; Shoko N; Jenkins S; Katanda Y; Xaba S; Mugurungi O
    BMC Infect Dis; 2023 Feb; 23(1):113. PubMed ID: 36823550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative Methods Used to Evaluate Impact of Combination HIV Prevention Intervention: A Methodological Systematic Review.
    Ravalihasy A; Ante-Testard PA; Kardas-Sloma L; Yazdanpanah Y; De Allegri M; Ridde V
    AIDS Behav; 2023 Aug; 27(8):2763-2773. PubMed ID: 36705772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of HIV and associated risk factors among street-connected children in Mwanza city.
    Nyumayo S; Konje E; Kidenya B; Kapesa A; Hingi M; Wango N; Ngimbwa J; Alphonce V; Basinda N
    PLoS One; 2022; 17(11):e0271042. PubMed ID: 36346792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.
    Garcia-Cremades M; Hendrix CW; Jayachandran P; Strydom N; Jarlsberg L; Grant R; Celum CL; Martin M; Baeten JM; Marrazzo J; Anderson P; Choopanya K; Vanichseni S; Glidden DV; Savic RM
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) Knowledge in Incarcerated Men.
    Valera P; Ali ZS; Cunningham D; McLaughlin C; Acevedo S
    Am J Mens Health; 2022; 16(4):15579883221107192. PubMed ID: 35796098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circumcision as an Intervening Strategy against HIV Acquisition in the Male Genital Tract.
    Sharma AL; Hokello J; Tyagi M
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34201976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Electrochemical Biosensors for the Detection of SARS-CoV-2 and Other Viruses.
    Imran S; Ahmadi S; Kerman K
    Micromachines (Basel); 2021 Feb; 12(2):. PubMed ID: 33578979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Mobile Gaming Intervention for Persons on Pre-Exposure Prophylaxis: Protocol for Intervention Development and Randomized Controlled Trial.
    Whiteley L; Olsen E; Mena L; Haubrick K; Craker L; Hershkowitz D; Brown LK
    JMIR Res Protoc; 2020 Sep; 9(9):e18640. PubMed ID: 32924954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.